Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Cholangiocarcinoma Clinical Trial

Official title:

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02924376
• Other study ID #: INCB 54828-202
• Status: Completed
• Phase: Phase 2
• Start date: January 16, 2017
• Est. completion date: February 1, 2022

Study information

• Verified date: January 2023
• Source: Incyte Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 147
• Est. completion date: February 1, 2022
• Est. primary completion date: February 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed cholangiocarcinoma.

• Radiographically measurable or evaluable disease per RECIST v1.1.

• Tumor assessment for FGF/FGFR gene alteration status.

• Documented disease progression after at least 1 line of prior systemic therapy.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Life expectancy = 12 weeks.

Exclusion Criteria:

• Prior receipt of a selective FGFR inhibitor.

• History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.

• Current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination.

• Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.

Related Conditions & MeSH terms

• Cholangiocarcinoma

Intervention

Drug:
• Pemigatinib
Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Incyte Corporation

Countries where clinical trial is conducted

United States,  Belgium,  France,  Germany,  Israel,  Italy,  Japan,  Korea, Republic of,  Spain,  Taiwan,  Thailand,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions	ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.	up to 1527 days
Secondary	ORR in Participants FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions	ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.	up to 424 days
Secondary	ORR in All Participants With FGF/FGFR Alterations	ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.	up to 1527 days
Secondary	ORR in Participants Negative for FGF/FGFR Alterations	ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.	up to 143 days
Secondary	Progression-free Survival (PFS)	PFS was defined as the length of time from the first dose of study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.	up to 50.17 months
Secondary	Duration of Response (DOR)	DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) as assessed by an independent centralized radiological review committee to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.	up to 47.11 months
Secondary	Disease Control Rate (DCR)	DCR was defined as the proportion of participants with an overall response of CR, PR, or stable disease (SD), per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.	up to 1527 days
Secondary	Overall Survival	Overall survival was defined as the length of time from the first dose of study drug (Day 1) until the date of death due to any cause.	up to 51.32 months
Secondary	Number of Participants With Any Treatment-emergent Adverse Event (TEAE)	An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was defined as any adverse event either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.	up to 1584 days
Secondary	First-order Absorption Rate Constant (ka) of Pemigatinib	First-order absorption rate constant is defined as the rate at which a drug enters into the system.	Predose; 1-2 hours post-dose; 4-12 hours post-dose
Secondary	CL/F of Pemigatinib	CL/F is defined as apparent oral clearance.	Predose; 1-2 hours post-dose; 4-12 hours post-dose
Secondary	Vc/F of Pemigatinib	Vc/F is defined as the apparent volume of distribution for the central compartment of pemigatinib.	Predose; 1-2 hours post-dose; 4-12 hours post-dose
Secondary	Vp/F of Pemigatinib	Vp/F is defined as the apparent volume of distribution for the tissue (peripheral) compartment.	Predose; 1-2 hours post-dose; 4-12 hours post-dose